Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective
Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been rep...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Molés-Poveda, P. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
Cutaneous graft versus host disease |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? - Madias, John E. ELSEVIER, 2014, Barcelona [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:109 ; year:2018 ; number:3 ; pages:241-247 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.adengl.2018.01.002 |
|---|
| Katalog-ID: |
ELV042550955 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042550955 | ||
| 003 | DE-627 | ||
| 005 | 20230624100116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.adengl.2018.01.002 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000186A.pica |
| 035 | |a (DE-627)ELV042550955 | ||
| 035 | |a (ELSEVIER)S1578-2190(18)30002-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 630 |a 640 |a 610 |q VZ |
| 100 | 1 | |a Molés-Poveda, P. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective |
| 264 | 1 | |c 2018 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. | ||
| 650 | 7 | |a Graft-versus-host disease |2 Elsevier | |
| 650 | 7 | |a Imatinib |2 Elsevier | |
| 650 | 7 | |a Treatment |2 Elsevier | |
| 650 | 7 | |a Cutaneous graft versus host disease |2 Elsevier | |
| 650 | 7 | |a Platelet-derived growth factor receptor |2 Elsevier | |
| 650 | 7 | |a Chronic sclerodermatous graft versus host disease |2 Elsevier | |
| 700 | 1 | |a Montesinos, P. |4 oth | |
| 700 | 1 | |a Sanz-Caballer, J. |4 oth | |
| 700 | 1 | |a de Unamuno, B. |4 oth | |
| 700 | 1 | |a Piñana, J.L. |4 oth | |
| 700 | 1 | |a Sahuquillo, A. |4 oth | |
| 700 | 1 | |a Botella-Estrada, R. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier España |a Madias, John E. ELSEVIER |t Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? |d 2014 |g Barcelona [u.a.] |w (DE-627)ELV012118117 |
| 773 | 1 | 8 | |g volume:109 |g year:2018 |g number:3 |g pages:241-247 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.adengl.2018.01.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_24 | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2018 |e 3 |h 241-247 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
p m p pmp |
|---|---|
| matchkey_str |
molspovedapmontesinospsanzcaballerjdeuna:2018----:ceoemtucrncrfvruhsdsaeraewtiaiiae |
| hierarchy_sort_str |
2018 |
| publishDate |
2018 |
| allfields |
10.1016/j.adengl.2018.01.002 doi GBV00000000000186A.pica (DE-627)ELV042550955 (ELSEVIER)S1578-2190(18)30002-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 630 640 610 VZ Molés-Poveda, P. verfasserin aut Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective 2018 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease Elsevier Montesinos, P. oth Sanz-Caballer, J. oth de Unamuno, B. oth Piñana, J.L. oth Sahuquillo, A. oth Botella-Estrada, R. oth Enthalten in Elsevier España Madias, John E. ELSEVIER Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? 2014 Barcelona [u.a.] (DE-627)ELV012118117 volume:109 year:2018 number:3 pages:241-247 extent:7 https://doi.org/10.1016/j.adengl.2018.01.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_24 AR 109 2018 3 241-247 7 045F 610 |
| spelling |
10.1016/j.adengl.2018.01.002 doi GBV00000000000186A.pica (DE-627)ELV042550955 (ELSEVIER)S1578-2190(18)30002-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 630 640 610 VZ Molés-Poveda, P. verfasserin aut Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective 2018 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease Elsevier Montesinos, P. oth Sanz-Caballer, J. oth de Unamuno, B. oth Piñana, J.L. oth Sahuquillo, A. oth Botella-Estrada, R. oth Enthalten in Elsevier España Madias, John E. ELSEVIER Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? 2014 Barcelona [u.a.] (DE-627)ELV012118117 volume:109 year:2018 number:3 pages:241-247 extent:7 https://doi.org/10.1016/j.adengl.2018.01.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_24 AR 109 2018 3 241-247 7 045F 610 |
| allfields_unstemmed |
10.1016/j.adengl.2018.01.002 doi GBV00000000000186A.pica (DE-627)ELV042550955 (ELSEVIER)S1578-2190(18)30002-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 630 640 610 VZ Molés-Poveda, P. verfasserin aut Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective 2018 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease Elsevier Montesinos, P. oth Sanz-Caballer, J. oth de Unamuno, B. oth Piñana, J.L. oth Sahuquillo, A. oth Botella-Estrada, R. oth Enthalten in Elsevier España Madias, John E. ELSEVIER Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? 2014 Barcelona [u.a.] (DE-627)ELV012118117 volume:109 year:2018 number:3 pages:241-247 extent:7 https://doi.org/10.1016/j.adengl.2018.01.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_24 AR 109 2018 3 241-247 7 045F 610 |
| allfieldsGer |
10.1016/j.adengl.2018.01.002 doi GBV00000000000186A.pica (DE-627)ELV042550955 (ELSEVIER)S1578-2190(18)30002-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 630 640 610 VZ Molés-Poveda, P. verfasserin aut Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective 2018 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease Elsevier Montesinos, P. oth Sanz-Caballer, J. oth de Unamuno, B. oth Piñana, J.L. oth Sahuquillo, A. oth Botella-Estrada, R. oth Enthalten in Elsevier España Madias, John E. ELSEVIER Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? 2014 Barcelona [u.a.] (DE-627)ELV012118117 volume:109 year:2018 number:3 pages:241-247 extent:7 https://doi.org/10.1016/j.adengl.2018.01.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_24 AR 109 2018 3 241-247 7 045F 610 |
| allfieldsSound |
10.1016/j.adengl.2018.01.002 doi GBV00000000000186A.pica (DE-627)ELV042550955 (ELSEVIER)S1578-2190(18)30002-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 630 640 610 VZ Molés-Poveda, P. verfasserin aut Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective 2018 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease Elsevier Montesinos, P. oth Sanz-Caballer, J. oth de Unamuno, B. oth Piñana, J.L. oth Sahuquillo, A. oth Botella-Estrada, R. oth Enthalten in Elsevier España Madias, John E. ELSEVIER Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? 2014 Barcelona [u.a.] (DE-627)ELV012118117 volume:109 year:2018 number:3 pages:241-247 extent:7 https://doi.org/10.1016/j.adengl.2018.01.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_24 AR 109 2018 3 241-247 7 045F 610 |
| language |
English |
| source |
Enthalten in Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? Barcelona [u.a.] volume:109 year:2018 number:3 pages:241-247 extent:7 |
| sourceStr |
Enthalten in Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? Barcelona [u.a.] volume:109 year:2018 number:3 pages:241-247 extent:7 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Graft-versus-host disease Imatinib Treatment Cutaneous graft versus host disease Platelet-derived growth factor receptor Chronic sclerodermatous graft versus host disease |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? |
| authorswithroles_txt_mv |
Molés-Poveda, P. @@aut@@ Montesinos, P. @@oth@@ Sanz-Caballer, J. @@oth@@ de Unamuno, B. @@oth@@ Piñana, J.L. @@oth@@ Sahuquillo, A. @@oth@@ Botella-Estrada, R. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV012118117 |
| dewey-sort |
3610 |
| id |
ELV042550955 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042550955</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624100116.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.adengl.2018.01.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000186A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042550955</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1578-2190(18)30002-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Molés-Poveda, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Graft-versus-host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Imatinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cutaneous graft versus host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Platelet-derived growth factor receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic sclerodermatous graft versus host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montesinos, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanz-Caballer, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Unamuno, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piñana, J.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sahuquillo, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Botella-Estrada, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier España</subfield><subfield code="a">Madias, John E. ELSEVIER</subfield><subfield code="t">Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome?</subfield><subfield code="d">2014</subfield><subfield code="g">Barcelona [u.a.]</subfield><subfield code="w">(DE-627)ELV012118117</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:109</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:241-247</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.adengl.2018.01.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">109</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">241-247</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Molés-Poveda, P. |
| spellingShingle |
Molés-Poveda, P. ddc 610 ddc 630 Elsevier Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective |
| authorStr |
Molés-Poveda, P. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012118117 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 630 - Agriculture & related technologies 640 - Home & family management |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 630 640 610 VZ Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease Elsevier |
| topic |
ddc 610 ddc 630 Elsevier Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease |
| topic_unstemmed |
ddc 610 ddc 630 Elsevier Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease |
| topic_browse |
ddc 610 ddc 630 Elsevier Graft-versus-host disease Elsevier Imatinib Elsevier Treatment Elsevier Cutaneous graft versus host disease Elsevier Platelet-derived growth factor receptor Elsevier Chronic sclerodermatous graft versus host disease |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p m pm j s c jsc u b d ub ubd j p jp a s as r b e rbe |
| hierarchy_parent_title |
Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? |
| hierarchy_parent_id |
ELV012118117 |
| dewey-tens |
610 - Medicine & health 630 - Agriculture 640 - Home & family management |
| hierarchy_top_title |
Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012118117 |
| title |
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective |
| ctrlnum |
(DE-627)ELV042550955 (ELSEVIER)S1578-2190(18)30002-7 |
| title_full |
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective |
| author_sort |
Molés-Poveda, P. |
| journal |
Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? |
| journalStr |
Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome? |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
241 |
| author_browse |
Molés-Poveda, P. |
| container_volume |
109 |
| physical |
7 |
| class |
610 610 DE-600 610 VZ 630 640 610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Molés-Poveda, P. |
| doi_str_mv |
10.1016/j.adengl.2018.01.002 |
| dewey-full |
610 630 640 |
| title_sort |
sclerodermatous chronic graft-versus-host disease treated with imatinib: a dermatological perspective |
| title_auth |
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective |
| abstract |
Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. |
| abstractGer |
Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. |
| abstract_unstemmed |
Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_24 |
| container_issue |
3 |
| title_short |
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective |
| url |
https://doi.org/10.1016/j.adengl.2018.01.002 |
| remote_bool |
true |
| author2 |
Montesinos, P. Sanz-Caballer, J. de Unamuno, B. Piñana, J.L. Sahuquillo, A. Botella-Estrada, R. |
| author2Str |
Montesinos, P. Sanz-Caballer, J. de Unamuno, B. Piñana, J.L. Sahuquillo, A. Botella-Estrada, R. |
| ppnlink |
ELV012118117 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.adengl.2018.01.002 |
| up_date |
2024-07-06T23:05:56Z |
| _version_ |
1803872796411953152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042550955</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624100116.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.adengl.2018.01.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000186A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042550955</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1578-2190(18)30002-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Molés-Poveda, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic graft-versus-host disease (cGVHD) is the most important cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD is usually steroid refractory and remains a therapeutic challenge. Activating antibodies against the PDGFR have been reported in patients with sclerodermatous cGVHD. These antibodies induce PDGFR phosphorylation and lead to fibrosis. There is increasing evidence of successful treatment of sclerodermatous cGVHD with imatinib, a tyrosine kinase inhibitor.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Graft-versus-host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Imatinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cutaneous graft versus host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Platelet-derived growth factor receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic sclerodermatous graft versus host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montesinos, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanz-Caballer, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Unamuno, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piñana, J.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sahuquillo, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Botella-Estrada, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier España</subfield><subfield code="a">Madias, John E. ELSEVIER</subfield><subfield code="t">Reserpine, mecamilamine, guanethidine, atropine for patients with Takotsubo syndrome?</subfield><subfield code="d">2014</subfield><subfield code="g">Barcelona [u.a.]</subfield><subfield code="w">(DE-627)ELV012118117</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:109</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:241-247</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.adengl.2018.01.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">109</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">241-247</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399349 |